Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?

Published:2013-08-30 Issue:3 Volume:129 Page:e12-e15
ISSN:0001-6314
Container-title:Acta Neurologica Scandinavica
language:en
Short-container-title:Acta Neurol Scand

Author:

Wipfler P.¹,Harrer A.¹,Pilz G.¹,Oppermann K.¹,Afazel S.²,Haschke-Becher E.²,Sellner J.¹³,Trinka E.¹,Kraus J.¹

Affiliation:

1. Department of Neurology; Christian-Doppler-Klinik; Paracelsus Medical University; Salzburg Austria

2. Central Laboratory; Christian-Doppler-Klinik; Paracelsus Medical University; Salzburg Austria

3. Department of Neurology; Klinikum rechts der Isar; Technische Universität München; Munich Germany

Publisher

Wiley

Subject

Clinical Neurology,Neurology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ane.12182/fullpdf

Reference13 articles.

1. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis;Polman;N Engl J Med,2006

2. Oral fingolimod (FTY720) for relapsing multiple sclerosis;Kappos;N Engl J Med,2006

3. Anti-JC virus antibodies: implications for PML risk stratification;Gorelik;Ann Neurol,2010

4. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis;O'Connor;Neurology,2011

5. Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis;Havla;J Neurol,2013

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Experimental laboratory biomarkers in multiple sclerosis;Wiener Medizinische Wochenschrift;2022-03-07

2. Natalizumab extended-interval dosing in multiple sclerosis to mitigate progressive multifocal leukoencephalopathy risk: initial study evidence and real-world experience;Journal of Central Nervous System Disease;2022-01

3. Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis;Journal of Neurology, Neurosurgery & Psychiatry;2020-10-14

4. Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring;Frontiers in Immunology;2020-09-24

5. Pharmacodynamics of natalizumab extended interval dosing in MS;Neurology - Neuroimmunology Neuroinflammation;2020-02-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3